Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.48 |
| ▸ | F10 | P00742 | 3/20 | 0.47 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.41 |
| ▸ | FAAH | O00519 | 2/20 | 0.40 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | F2 | P00734 | 1/20 | 0.38 |
| ▸ | ELANE | P08246 | 1/20 | 0.38 |
| ▸ | SLC26A4 | O43511 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | CCR3 | P51677 | 2/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1035911 | 1.00 | CYP3A4 (0.48) | CYP3A4CYP2D6F10CSNK1EFAAH | |
| SCHEMBL1076930 | 0.95 | CYP3A4 (0.50) | CYP3A4CYP2D6F10CSNK1EFAAH | |
| SCHEMBL1076929 | 0.95 | CYP3A4 (0.50) | CYP3A4CYP2D6F10CSNK1EFAAH | |
| SCHEMBL1035832 | 0.93 | CYP3A4 (0.49) | CYP3A4CYP2D6F10FAAH | |
| SCHEMBL1035831 | 0.93 | CYP3A4 (0.49) | CYP3A4CYP2D6F10FAAH | |
| SCHEMBL1038631 | 0.92 | CYP3A4 (0.47) | CYP3A4CYP2D6F10FAAHALDH1A1 | |
| SCHEMBL1038632 | 0.92 | CYP3A4 (0.47) | CYP3A4CYP2D6F10FAAHALDH1A1 | |
| SCHEMBL1040203 | 0.91 | CYP3A4 (0.44) | CYP3A4CYP2D6F10FAAHSIRT2 | |
| SCHEMBL1040202 | 0.91 | CYP3A4 (0.44) | CYP3A4CYP2D6F10FAAHSIRT2 | |
| SCHEMBL1039863 | 0.91 | FAAH (0.48) | CYP3A4CYP2D6F10FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110144159-A1 | ETHER BENZYLIDENE PIPERIDINE ARYL CARBOXAMIDE COMPOUNDS USEFUL AS FAAH INHIBITORS | PFIZER INC | 2011-06-16 | — | — | US | disclosed |
| EP-2276735-A1 | ETHER BENZYLIDENE PIPERIDINE ARYL CARBOXAMIDE COMPOUNDS USEFUL AS FAAH INHIBITORS | Pfizer Inc. (US) | 2011-01-26 | — | — | EP | disclosed |
| WO-2009127944-A1 | ETHER BENZYLIDENE PIPERIDINE ARYL CARBOXAMIDE COMPOUNDS USEFUL AS FAAH INHIBITORS | PFIZER INC. (US) | 2009-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144159-A1 | ETHER BENZYLIDENE PIPERIDINE ARYL CARBOXAMIDE COMPOUNDS USEFUL AS FAAH INHIBITORS | FAAH, FAAH2, PAH | CYP3A4 329/4885CYP2D6 382/4885F10 1979/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.